Redox regulation in stem-like cancer cells by CD44 variant isoforms

Oncogene

Volumn 32, Issue 44, 2013, Pages 5191-5198

  Nagano, O ^a   Okazaki, S ^a   Saya, H ^a,b  

^a KEIO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

cancer stem cell; CD44; cystine glutamate transporter; reactive oxygen species

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CD44V ANTIGEN; CELL SURFACE PROTEIN; CYSTEINE; CYSTINE; ERM PROTEIN; EZRIN; FLUORINE 18; GLUTAMATE TRANSPORTER; GLUTATHIONE; GLUTATHIONE SYNTHASE; MICRORNA; MICRORNA 373; MICRORNA 520C; MOESIN; NATURAL PRODUCT; PHENETHYL ISOTHIOCYANATE; PIPELONGUMINE; PLATINUM COMPLEX; RADIXIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CELL CULTURE; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; LUNG NON SMALL CELL CANCER; MACROPHAGE; MAMMAL CELL; METASTASIS; MITOCHONDRIAL RESPIRATION; NEUTROPHIL; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; REVIEW; RNA INTERFERENCE; TUMOR CELL; TUMOR GROWTH;

ANTIGENS, CD44; BIOLOGICAL TRANSPORT; CELL HYPOXIA; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; OXIDATION-REDUCTION; PROTEIN ISOFORMS; REACTIVE OXYGEN SPECIES;

EID: 84887043495     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.638     Document Type: Review

References (115)

1. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011; 17: 313-319.
2. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
3. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008; 359: 2814-2823.
4. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127: 679-695. (Pubitemid 44781029)
5. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009; 8: 579-591.
6. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008; 8: 545-554. (Pubitemid 351881850)
7. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458: 780-783.
8. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44\+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98: 1777-1785.
9. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007; 18: 460-466. (Pubitemid 350116595)
10. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007; 23: 675-699.
11. Zoller M. CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11: 254-267.
12. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988. (Pubitemid 36418143)
13. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951. (Pubitemid 41713363)
14. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104: 10158-10163. (Pubitemid 47175279)
15. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973-978. (Pubitemid 46154721)
16. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
17. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61: 1303-1313.
18. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004; 95: 930-935. (Pubitemid 40089583)
19. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4: 33-45. (Pubitemid 36077255)
20. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 2009; 33: 591-601.
21. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24. (Pubitemid 121001209)
22. Reber S, Matzku S, Gunthert U, Ponta H, Herrlich P, Zoller M. Retardation of metastatic tumor growth after immunization with metastasis-specific monoclonal antibodies. Int J Cancer 1990; 46: 919-927.
23. Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993; 177: 443-455. (Pubitemid 23117094)
24. Tanabe KK, Ellis LM, Saya H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 1993; 341: 725-726. (Pubitemid 23085181)
25. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12: 1167-1174. (Pubitemid 44527352)
26. Preston M, Sherman LS. Neural stem cell niches: roles for the hyaluronan-based extracellular matrix. Front Biosci 2011; 3: 1165-1179.
27. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood 2005; 106: 1901-1910. (Pubitemid 41291700)
28. Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008; 14: 181-187. (Pubitemid 351214550)
29. DeGrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997; 278: 672-675. (Pubitemid 27464963)
30. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011; 19: 387-400.
31. Shi X, Zhang Y, Zheng J, Pan J. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal 2012; 16: 1215-1228.
32. Mielgo A, van Driel M, Bloem A, Landmann L, Gunthert U. A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ 2006; 13: 465-477.
33. Bourguignon LY, Earle C, Wong G, Spevak CC, Krueger K. Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene 2012; 31: 149-160.
34. Toole BP, Slomiany MG. Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Update 2008; 11: 110-121.
35. Pham PV, Phan NL, Nguyen NT, Truong NH, Duong TT, Le DV et al. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med 2011; 9: 209.
36. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17: 211-215.
37. Ohata H, Ishiguro T, Aihara Y, Sato A, Sakai H, Sekine S et al. Induction of the stem-like cell regulator CD44 by Rho kinase inhibition contributes to the maintenance of colon cancer-initiating cells. Cancer Res 2012; 72: 5101-5110.
38. Du L, Wang H, He L, Zhang J, Ni B, Wang X et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008; 14: 6751-6760.
39. Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/\+) mice attenuates intestinal tumorigenesis. Cancer Res 2008; 68: 3655-3661.
40. Lopez JI, Camenisch TD, Stevens MV, Sands BJ, McDonald J, Schroeder JA. CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res 2005; 65: 6755-6763. (Pubitemid 41060713)
41. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006; 6: 637-645. (Pubitemid 44140861)
42. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-1784. (Pubitemid 38063698)
43. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
44. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
45. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011; 121: 1064-1074.
46. Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay MH et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 2011; 7: e1002218.
47. Warzecha CC, Jiang P, Amirikian K, Dittmar KA, Lu H, Shen S et al. An ESRPregulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J 2010; 29: 3286-3300.
48. Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H et al. CD44s regulates the TGF-b-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res 2012; 72: 3414-3423.
49. Takahashi E, Nagano O, Ishimoto T, Yae T, Suzuki Y, Shinoda T et al. Tumor necrosis factor-a regulates transforming growth factor-b-dependent epithelialmesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem 2010; 285: 4060-4073.
50. Bartolazzi A, Jackson D, Bennett K, Aruffo A, Dickinson R, Shields J et al. Regulation of growth and dissemination of a human lymphoma by CD44 splice variants. J Cell Sci 1995; 108: 1723-1733.
51. Bennett KL, Modrell B, Greenfield B, Bartolazzi A, Stamenkovic I, Peach R et al. Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J Cell Biol 1995; 131: 1623-1633. (Pubitemid 26001764)
52. Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun 2012; 3: 883.
53. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ et al. Direct regulation of TWIST by HIF-1a promotes metastasis. Nat Cell Biol 2008; 10: 295-305.
54. Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by Met signaling pathway. Cancer Cell 2012; 21: 66-81.
55. Sun S, Ning X, Zhang Y, Lu Y, Nie Y, Han S et al. Hypoxia-inducible factor-1a induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition. Kidney Int 2009; 75: 1278-1287.
56. Krishnamachary B, Penet MF, Nimmagadda S, Mironchik Y, Raman V, Solaiyappan M et al. Hypoxia regulates CD44 and its variant isoforms through HIF-1a in triple negative breast cancer. PLoS One 2012; 7: e44078.
57. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527. (Pubitemid 44854747)
58. Kannagi R, Sakuma K, Miyazaki K, Lim KT, Yusa A, Yin J et al. Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: clues in the ongoing search for new tumor markers. Cancer Sci 2010; 101: 586-593.
59. Hanley WD, Burdick MM, Konstantopoulos K, Sackstein R. CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity. Cancer Res 2005; 65: 5812-5817. (Pubitemid 40911185)
60. Bennett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Modrell B et al. CD44 isoforms containing exon V3 are responsible for the presentation of heparinbinding growth factor. J Cell Biol 1995; 128: 687-698.
61. Yu WH, Woessner Jr JF, McNeish JD, Stamenkovic I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 2002; 16: 307-323. (Pubitemid 34111411)
62. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002; 16: 3074-3086. (Pubitemid 35424194)
63. Slomiany MG, Grass GD, Robertson AD, Yang XY, Maria BL, Beeson C et al. Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res 2009; 69: 1293-1301.
64. Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, Miyamoto K et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 2006; 12: 446-451.
65. Tothova Z, Gilliland DG. FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell 2007; 1: 140-152. (Pubitemid 47215597)
66. Owusu-Ansah E, Banerjee U. Reactive oxygen species prime Drosophila haematopoietic progenitors for differentiation. Nature 2009; 461: 537-541.
67. Macleod KF. The role of the RB tumour suppressor pathway in oxidative stress responses in the haematopoietic system. Nat Rev Cancer 2008; 8: 769-781.
68. Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, Nakayama K et al. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 2006; 8: 1291-1297. (Pubitemid 44660595)
69. Li J, Stouffs M, Serrander L, Banfi B, Bettiol E, Charnay Y et al. The NADPH oxidase NOX4 drives cardiac differentiation: role in regulating cardiac transcription factors and MAP kinase activation. Mol Biol Cell 2006; 17: 3978-3988. (Pubitemid 44330881)
70. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007; 129: 465-472. (Pubitemid 46660978)
71. Hill RP, Marie-Egyptienne DT, Hedley DW. Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 2009; 19: 106-111.
72. Adam-Vizi V, Chinopoulos C. Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol Sci 2006; 27: 639-645. (Pubitemid 44767940)
73. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell 2005; 120: 483-495. (Pubitemid 40269763)
74. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
75. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011; 475: 106-109.
76. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, Nebreda AR. p38a MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 2007; 11: 191-205. (Pubitemid 46209847)
77. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000; 279: L1005-L1028. (Pubitemid 32009487)
78. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313. (Pubitemid 46209993)
79. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011; 71: 2411-2416.
80. Spitz DR, Azzam EI, Li JJ, Gius D. Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology. Cancer Metast Rev 2004; 23: 311-322. (Pubitemid 38881814)
81. Golden EB, Pellicciotta I, Demaria S, Barcellos-Hoff MH, Formenti SC. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol 2012; 2: 88.
82. Hendry JH, West CM. Apoptosis and mitotic cell death: their relative contributions to normal-tissue and tumour radiation response. Int J Radiat Biol 1997; 71: 709-719. (Pubitemid 27306026)
83. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 2004; 3: 294-300. (Pubitemid 39552423)
84. Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, Hirai T et al. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 1999; 274: 7936-7940.
85. Arrick BA, Nathan CF. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res 1984; 44: 4224-4232. (Pubitemid 14008726)
86. Dalton TP, Chen Y, Schneider SN, Nebert DW, Shertzer HG. Genetically altered mice to evaluate glutathione homeostasis in health and disease. Free Radic Biol Med 2004; 37: 1511-1526. (Pubitemid 39349798)
87. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988; 263: 17205-17208. (Pubitemid 19029311)
88. O'Brien ML, Tew KD. Glutathione and related enzymes in multidrug resistance. Eur J Cancer 1996; 32A: 967-978.
89. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994; 54: 4313-4320. (Pubitemid 24273141)
90. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011; 475: 231-234.
91. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by b-phenylethyl isothiocyanate. Cancer Cell 2006; 10: 241-252. (Pubitemid 44311067)
92. Huang Y, Dai Z, Barbacioru C, Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 2005; 65: 7446-7454. (Pubitemid 41161279)
93. Lo M, Wang YZ, Gout PW. The x(c)-cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol 2008; 215: 593-602. (Pubitemid 351632680)
94. Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y et al. Redox imbalance in cystine/glutamate transporter-deficient mice. J Biol Chem 2005; 280: 37423-37429. (Pubitemid 41642349)
95. Ishii T, Sugita Y, Bannai S. Regulation of glutathione levels in mouse spleen lymphocytes by transport of cysteine. J Cell Physiol 1987; 133: 330-336. (Pubitemid 18000329)
96. Sasaki H, Sato H, Kuriyama-Matsumura K, Sato K, Maebara K, Wang H et al. Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J Biol Chem 2002; 277: 44765-44771. (Pubitemid 36159069)
97. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 2003; 11: 619-633. (Pubitemid 36385118)
98. Lewerenz J, Sato H, Albrecht P, Henke N, Noack R, Methner A et al. Mutation of ATF4 mediates resistance of neuronal cell lines against oxidative stress by inducing xCT expression. Cell Death Differ 2012; 19: 847-858.
99. Lewerenz J, Maher P. Basal levels of eIF2a phosphorylation determine cellular antioxidant status by regulating ATF4 and xCT expression. J Biol Chem 2009; 284: 1106-1115.
100. Wang H, Tamba M, Kimata M, Sakamoto K, Bannai S, Sato H. Expression of the activity of cystine/glutamate exchange transporter, system x(c)(-), by xCT and rBAT. Biochem Biophys Res Commun 2003; 305: 611-618. (Pubitemid 36579275)
101. Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y. CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch 2004; 447: 532-542. (Pubitemid 38258215)
102. Baek S, Choi CM, Ahn SH, Lee JW, Gong G, Ryu JS et al. Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC-transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin Cancer Res 2012; 18: 5427-5437.
103. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006; 12: 5615-5621. (Pubitemid 44629587)
104. Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011; 9: 357-365.
105. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323. (Pubitemid 47355323)
106. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 2009; 13: 2236-2252.
107. Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, Lin J et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci USA 2010; 107: 18115-18120.
108. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S et al. Highly purified CD44\+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25: 1696-1708.
109. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008; 18: 260-267.
110. Weber GF, Bronson RT, Ilagan J, Cantor H, Schmits R, Mak TW. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res 2002; 62: 2281-2286. (Pubitemid 34411705)
111. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008; 10: 202-210. (Pubitemid 351194050)
112. Qu Y, Wang J, Ray PS, Guo H, Huang J, Shin-Sim M et al. Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-kB signaling. J Clin Invest 2011; 121: 212-225.
113. Granot Z, Henke E, Comen EA, King TA, Norton L, Benezra R. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 2011; 20: 300-314.
114. Anasagasti MJ, Martin JJ, Mendoza L, Obrador E, Estrela JM, McCuskey RS et al. Glutathione protects metastatic melanoma cells against oxidative stress in the murine hepatic microvasculature. Hepatology 1998; 27: 1249-1256. (Pubitemid 28227851)
115. Obrador E, Carretero J, Ortega A, Medina I, Rodilla V, Pellicer JA et al. g-Glutamyl transpeptidase overexpression increases metastatic growth of B16 melanoma cells in the mouse liver. Hepatology 2002; 35: 74-81. (Pubitemid 34032545)